Prime Medicine Inc (NASDAQ: PRME) kicked off on Monday, up 12.57% from the previous trading day, before settling in for the closing price of $3.74. Over the past 52 weeks, PRME has traded in a range of $1.11-$6.94.
During the last 5-year period, the sales drop of Healthcare Sector giant was -124.13%. While this was happening, its average annual earnings per share was recorded 20.24%. With a float of $93.82 million, this company’s outstanding shares have now reached $180.31 million.
Prime Medicine Inc (PRME) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Prime Medicine Inc is 48.03%, while institutional ownership is 38.15%. The most recent insider transaction that took place on Aug 01 ’25, was worth 4,950,000. In this transaction 10% Owner of this company bought 1,500,000 shares at a rate of $3.30, taking the stock ownership to the 3,262,440 shares. Before that another transaction happened on Aug 01 ’25, when Company’s Director bought 3,030,300 for $3.30, making the entire transaction worth $9,999,990. This insider now owns 6,230,300 shares in total.
Prime Medicine Inc (PRME) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.31 earnings per share (EPS), higher than consensus estimate (set at -0.31) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.95% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Take a look at Prime Medicine Inc’s (PRME) current performance indicators. Last quarter, stock had a quick ratio of 6.61. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 127.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.48, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.93 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Looking closely at Prime Medicine Inc (NASDAQ: PRME), its last 5-days average volume was 4.4 million, which is a jump from its year-to-date volume of 2.93 million. As of the previous 9 days, the stock’s Stochastic %D was 74.54%.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 29.19%, which indicates a significant decrease from 93.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.32 in the past 14 days, which was lower than the 0.41 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.70, while its 200-day Moving Average is $3.17. However, in the short run, Prime Medicine Inc’s stock first resistance to watch stands at $4.38. Second resistance stands at $4.56. The third major resistance level sits at $4.83. If the price goes on to break the first support level at $3.93, it is likely to go to the next support level at $3.66. Now, if the price goes above the second support level, the third support stands at $3.48.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
The company with the Market Capitalisation of 759.95 million has total of 180,511K Shares Outstanding. Its annual sales at the moment are 2,980 K in contrast with the sum of -195,880 K annual income. Company’s last quarter sales were recorded 1,230 K and last quarter income was -50,580 K.
